ChemGenex, MolecularMD to identify leukemia patients with T315I mutation for phase 2/ 3 trial

By Lisa Kerner

Charlotte, N.C., June 26 - ChemGenex Pharmaceuticals said it has formed an alliance with MolecularMD, Inc. to identify chronic myeloid leukemia (CML) patients with the T315I bcr-abl mutation as possible candidates for ChemGenex's phase 2/ 3 study of Ceflatonin.

T315I expressing cells are resistant to the tyrosine kinase inhibitor imatinib (Gleevec). In addition, preliminary data suggest that CML patients with the T315I point mutation don't respond to either of two second generation tyrosine kinase inhibitors in clinical development.

Ceflatonin has demonstrated clinical activity in human clinical studies for patients not responding to Gleevec, according to a company news release.

ChemGenex, located in Melbourne, Australia, develops therapeutics in the areas of oncology, diabetes, obesity, and depression.

Based in Portland, Ore., MolecularMD provides molecular diagnostic services, including drug resistance mutation screening for chronic myeloid leukemia patients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.